Telix Pharmaceuticals Limited (ASX:TLX) Completes Acquisition of FAP-targeting Theranostic Candidates
Deal Details
Telix Pharmaceuticals has completed the acquisition of FAP-targeting theranostic candidates, enhancing its nuclear medicine pipeline. The transaction includes asset purchase and exclusive worldwide in-license agreements for clinically validated FAP-targeting radiopharmaceuticals.
Pipeline Expansion
The company has added TLX400, a lead FAP-targeting therapeutic compound, to its portfolio. Telix is developing a theranostic program in bladder cancer as part of its urology focus and exploring pan-cancer therapeutic opportunities across multiple solid tumour indications. The acquired compounds have shown extended tumor retention and reduced off-target uptake in over 500 patients.
Executive Comments
Chief Executive Officer, Therapeutics, Richard Valeix, stated, “We are pleased to have finalized this transaction so that we can continue to leverage the FAP-targeting research pioneered by Professor Rösch and his team. We believe this technology holds great promise for both imaging and treating tumors, and Telix is now focused on using these compounds to build out our urology franchise and explore pan-cancer opportunities, with the goal of bringing new theranostic solutions to physicians and their patients.”
Motley Fool contributor Matt Burgess has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Telix Pharmaceuticals. The Motley Fool Australia has recommended Telix Pharmaceuticals. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
This article was generated using GPT-4o mini, a Large Language Model (LLM), to generate summaries of investing news. While AI is generating the content, we know better than to blindly trust our future robot overlords, and every article is edited and fact-checked by an editor holding the appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content of everything published by The Capital Club.